Research and Markets (http://www.researchandmarkets.com/research/v9tpmg/tgfbeta_receptor) has announced the addition of the "TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2015" report to their offering.
The TGF-beta receptor signaling pathway activates the MAPK/SMAD signaling modules.
There are today 305 companies plus partners developing 367 TGF-beta receptor pathway targeting drugs in 1529 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 257 drugs.
TGF-Beta Receptor Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 242 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 234 out of the 237 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 53 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 35
- Registered - 1
- Pre-registration - 6
- Phase III - 32
- Phase II - 151
- Phase I - 162
- Preclinical - 197
- No Data - 14
- Suspended - 2
-
Ceased - 257
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/v9tpmg/tgfbeta_receptor
